ADAM17 and neoplasm: Though inhibition of the MAPK14/ADAM17 pathway significantly attenuated the CX3CL1 secretion advantage of VBMECs conferred by tumor cells, CX3CL1 expression in VBMECs was still upregulated in the co-culture system compared with controls, even in the presence of the MAPK14 inhibitor SB203580 or with ADAM17 inhibition (Figure 6G-H, and 6J).